US rejects ‘FDA for AI’, says approvals could slow innovation
- The US has opposed creating an “FDA for AI” at a G20 session on emerging technologies.
- Former White House AI czar David Sacks said pre-approval rules could slow AI development and hurt innovation.
- Sacks argued that governments should use existing laws and regulatory agencies to address AI-related risks.
- He said AI models are developing too quickly for a system that requires advance government approval, while suggesting transparency, audits and disclosures instead.
Source: ianslive.in
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
